What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity.
BACKGROUND
A major handicap in developing a malaria vaccine is the difficulty in pinpointing the immune responses that protect against malaria. The protective efficacy of natural or vaccine-induced immune responses against malaria is normally assessed by relating the level of the responses in an individual at the beginning of a follow-up period and the individual's experience of malaria infection or disease during the follow-up. This approach has identified a number of important responses against malaria, but their protective efficacies vary considerably between studies.


OBJECTIVE
It is likely that apart from differences in study methodologies, differences in exposure among study subjects within each study and brevity of antibody responses to malaria antigen are important sources of the variation in protective efficacy of anti-malaria immune responses mentioned above. Since malaria immunity is not complete, anyone in an area of stable malaria transmission who does not become asymptomatically or symptomatically infected during follow-up subsequent to treatment is most likely unexposed rather than immune.


METHODS
It is proposed that individuals involved in a longitudinal study of malaria immunity should be treated for malaria prior to the start of the study and only those who present with at least an asymptomatic infection during the follow-up should be included in the analysis. In addition, it is proposed that more closely repeated serological survey should be carried out during follow-up in order to get a better picture of an individual's serological status.


CONCLUSIONS
Failure to distinguish between individuals who do not get a clinical episode during follow-up because they were unexposed and those who are genuinely immune undermines our ability to assign a protective role to immune responses against malaria. The brevity of antibodies responses makes it difficult to assign the true serological status of an individual at any given time, i.e. those positive at a survey may be negative by the time they encounter the next infection.
Kinyanjui
Samson M
SM
Kenyan Medical Research Institute (KEMRI), Centre for Geographic Medicine Research (Coast), PO Box 230, Kilifi 80108, Kenya. skmuchina@kilifi.kemri-wellcome.org
Bejon
Philip
P
Osier
Faith H
FH
Bull
Peter C
PC
Marsh
Kevin
K
D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D008137:Longitudinal Studies; D008288:Malaria / Q000276:immunology* / Q000517:prevention & control*; D012107:Research Design
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan